This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/resource/domain/vavai/subjekt/
n5http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n13http://bibframe.org/vocab/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F13%3A10193779%21RIV14-MZ0-00064165/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F13%3A10193779%21RIV14-MZ0-00064165
rdf:type
n5:Vysledek skos:Concept
rdfs:seeAlso
http://dx.doi.org/10.3109/00365521.2013.812141
dcterms:description
Objective. Substantial number of women with inflammatory bowel disease (IBD) conceives while on anti-TNF-alpha therapy. The aim was to assess the safety and efficacy of anti-TNF-alpha treatment during pregnancy and to analyze relationship of neonatal and maternal anti-TNF-alpha levels at delivery with gestational age at the last exposure. Material and methods. Women with IBD exposed to anti-TNF-alpha therapy during pregnancy were included. Data on anti-TNF-alpha treatment, disease activity, concomitant medication, pregnancy and newborn outcome were recorded. Anti-TNF-alpha levels from cord blood were assessed by ELISA. Results. Forty-one pregnancies (27 Crohn's disease; 14 ulcerative colitis) were exposed to infliximab (IFX; 32) and adalimumab (ADA; 9). Ten (24%) women had active disease at conception and 31 (76%) were in remission with 3 patients experiencing relapse during pregnancy. Anti-TNF-alpha therapy started prior to and after conception in 32 and 9 women, respectively. There were 34 (83%) live births (median birth weight 3145 g) of which 28 were at-term and 6 preterm deliveries. Five (12%) pregnancies ended in spontaneous and two in therapeutic abortion. No congenital malformations except for one case of hip dysplasia were observed. Similarly, no serious perinatal complication occurred. IFX cord levels measured in 11 children positively correlated with gestational week at the last drug administration and maternal levels at delivery, while no such correlation was found in case of ADA. Conclusions. The results confirm that anti-TNFs are effective and safe during pregnancy. A positive correlation between IFX cord levels and gestational week of last exposure as well as maternal serum levels was observed. Objective. Substantial number of women with inflammatory bowel disease (IBD) conceives while on anti-TNF-alpha therapy. The aim was to assess the safety and efficacy of anti-TNF-alpha treatment during pregnancy and to analyze relationship of neonatal and maternal anti-TNF-alpha levels at delivery with gestational age at the last exposure. Material and methods. Women with IBD exposed to anti-TNF-alpha therapy during pregnancy were included. Data on anti-TNF-alpha treatment, disease activity, concomitant medication, pregnancy and newborn outcome were recorded. Anti-TNF-alpha levels from cord blood were assessed by ELISA. Results. Forty-one pregnancies (27 Crohn's disease; 14 ulcerative colitis) were exposed to infliximab (IFX; 32) and adalimumab (ADA; 9). Ten (24%) women had active disease at conception and 31 (76%) were in remission with 3 patients experiencing relapse during pregnancy. Anti-TNF-alpha therapy started prior to and after conception in 32 and 9 women, respectively. There were 34 (83%) live births (median birth weight 3145 g) of which 28 were at-term and 6 preterm deliveries. Five (12%) pregnancies ended in spontaneous and two in therapeutic abortion. No congenital malformations except for one case of hip dysplasia were observed. Similarly, no serious perinatal complication occurred. IFX cord levels measured in 11 children positively correlated with gestational week at the last drug administration and maternal levels at delivery, while no such correlation was found in case of ADA. Conclusions. The results confirm that anti-TNFs are effective and safe during pregnancy. A positive correlation between IFX cord levels and gestational week of last exposure as well as maternal serum levels was observed.
dcterms:title
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study
skos:prefLabel
Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study
skos:notation
RIV/00064165:_____/13:10193779!RIV14-MZ0-00064165
n5:predkladatel
n17:ico%3A00064165
n3:aktivita
n7:I n7:S
n3:aktivity
I, S
n3:cisloPeriodika
8
n3:dodaniDat
n15:2014
n3:domaciTvurceVysledku
n19:9451935
n3:druhVysledku
n6:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n16:predkladatel
n3:idSjednocenehoVysledku
98801
n3:idVysledku
RIV/00064165:_____/13:10193779
n3:jazykVysledku
n14:eng
n3:klicovaSlova
pregnancy; outcome; infliximab; inflammatory bowel disease; adalimumab
n3:klicoveSlovo
n9:pregnancy n9:adalimumab n9:inflammatory%20bowel%20disease n9:infliximab n9:outcome
n3:kodStatuVydavatele
GB - Spojené království Velké Británie a Severního Irska
n3:kontrolniKodProRIV
[025F5146CB11]
n3:nazevZdroje
Scandinavian Journal of Gastroenterology
n3:obor
n11:EC
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
9
n3:rokUplatneniVysledku
n15:2013
n3:svazekPeriodika
48
n3:tvurceVysledku
Machková, Naděžda Ďuricová, Dana Shonová, Olga Lukáš, Milan Hrdlička, Luděk Lukáš, Martin Bortlík, Martin Malíčková, Karin Kohout, Pavel
n3:wos
000322850500008
s:issn
0036-5521
s:numberOfPages
8
n13:doi
10.3109/00365521.2013.812141